GSK2945 is a highly selective Rev-erbα antagonist used to enhance cholesterol 7α-hydroxylase (CYP7A1) expression and promote cholesterol metabolism; it increases transcriptional activity of Rev-erbα and its target gene Bmal1; upregulates LRH-1 (a hepatic activator of CYP7A1) mRNA and protein levels in mouse and human primary hepatocytes; and reduces plasma cholesterol while increasing hepatic Cyp7a1 levels in wild-type mice.